8-K
filed October 14, 2025, 7:59 PM ET
ticker RNAZ
CIK 0001829635
other material
confidence high
sentiment positive
materiality 0.75
TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a
Transcode Therapeutics, Inc.
- 16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
- Median treatment duration of 4 months (range 2–12); three patients remain on trial.
- 44% (7/16) achieved stable disease lasting ≥4 months per RECIST; one thyroid cancer patient had undetectable thyroglobulin.
- Recommended Phase 2 dose established; company plans to initiate Phase 2a efficacy trial.
- PK profile shows predictable exposure; pharmacodynamic effects consistent with preclinical models and prior Phase 0.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001104659-25-099029
- form_type
- 8-K
- ticker
- RNAZ
- cik
- 0001829635
- company_name
- Transcode Therapeutics, Inc.
- filed_at
- 2025-10-14T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:40.670649+00:00
- generated_at
- 2026-05-17T03:58:03.783036+00:00
- sec_items
- ["8.01", "9.01"]
- event_type
- other_material
- sentiment
- positive
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001104659-25-099029
- json_url
- https://secwatch.observer/filing/0001104659-25-099029.json
- markdown_url
- https://secwatch.observer/filing/0001104659-25-099029.md
- text_url
- https://secwatch.observer/filing/0001104659-25-099029.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/0001104659-25-099029-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1829635/000110465925099029/tm2528668d1_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
PECE
Peace Acquisition Corp closes IPO of 6M units at $10.00/unit, raising $60M
Peace Acquisition Corp.
June 1, 2026, 5:16 PM ET
other_material
Items 3.02, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MVIS
MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026
MICROVISION, INC.
June 1, 2026, 5:02 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VDTA
Vertical Data launches Vertical Edge, a direct-ownership edge data center platform
Vertical Data Inc.
June 1, 2026, 4:47 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
XAIR
Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026
Beyond Air, Inc.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CSR
Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City
CENTERSPACE
June 1, 2026, 4:30 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
IDYA
IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma
IDEAYA Biosciences, Inc.
June 1, 2026, 4:05 PM ET
other_material
Items 7.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.